Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's disease

This page shows the latest Alzheimer's disease news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

Merck Research Laboratories president Roger Perlmutter said the company is "disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer's disease.". ... Meanwhile, verubecestat’s demise follows a

Latest news

  • Boehringer abandons PDE-targeted Alzheimer’s drug Boehringer abandons PDE-targeted Alzheimers drug

    Boehringer abandons PDE-targeted Alzheimer’ s drug. But will keep testing the candidate in schizophrenia. ... Boehringer Ingelheim has said it will halt development of its Alzheimer’s disease drug BI 409306 after it failed to hit the mark in

  • Takeda and Zinfandel abandon Alzheimer’s drug Takeda and Zinfandel abandon Alzheimers drug

    Takeda and Zinfandel abandon Alzheimer’ s drug. Pioglitazone failed to show therapeutic improvements in late-stage testing. ... A phase III trial of pioglitazone in Alzheimer’s disease has been terminated by Takeda and partner Zinfandel Therapeutics

  • Takeda ties-up with Denali Therapeutics for neuroscience boost Takeda ties-up with Denali Therapeutics for neuroscience boost

    Takeda ties-up with Denali Therapeutics for neuroscience boost. The companies will develop new therapies for conditions such as Alzheimer’s. ... The collaboration will see the companies produce up to three specified therapeutic product candidates which

  • Boehringer adds to pipeline again with €628m Autifony CNS deal Boehringer adds to pipeline again with €628m Autifony CNS deal

    Boehringer adds to pipeline again with 628m Autifony CNS deal. Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia. ... of mental disorders, such as schizophrenia, Alzheimer’s disease and depression, ”he added.

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    The partners recently suffered a big setback in their plans for brexpiprazole after the drug posted mixed results in agitation in Alzheimer’s disease patients, a condition that affects millions of

More from news
Approximately 52 fully matching, plus 314 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... for local administration for the

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinson’s house'

    But this elegant home, surrounded by manicured lawns, is wired to beat the scourge of Parkinson’s disease. ... Since this article was written Pfizer has substantially scaled back its neuroscience R&D work into conditions such as Parkinson's and

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimers advances

    All we really know is that evidence of amyloid deposition begins up to maybe 20 years before the onset of Alzheimer’s disease. ... Of course, the possibility remains that neither tau nor amyloid are responsible for the development of Alzheimer’s

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    The in-partnering deals included the $1bn deal with Bicycle Therapeutics and the Alzheimer's collaboration with Lilly. ... development agreement with AstraZeneca for a phase I antibody selective for amyloid-beta 42 in Alzheimer's disease.

  • Behavioural science in 2030 Behavioural science in 2030

    And I posit that this should be addressed through a further evolution of the novel adaptive licensing strategies currently being trialled in Alzheimer's disease and breast cancer. ... has brought us ever closer to exquisite precision in disease diagnosis

More from intelligence
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest appointments

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Alzheimer's disease. ... His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease. “ ... disease.”. 20th June 2016.

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai has also appointed Beyhan Zaim to its US Neurology Business Group as VP, commercial development and Alzheimer's Disease global lead. ... As global lead for Alzheimer's Disease she will also be tasked with developing strategies and heading internal

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

  • Alzheimers disease: reviewing the immediate treatment horizon

    Alzheimer’ s disease: reviewing the immediate treatment horizon. Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to ... A recent article by BLH Consultant David Cooney

  • Alzheimer's: the numbers we cannot forget

    I would love to be talking about our latest thinking around launching new therapies in Alzheimer’ s disease (AD) but I can’ t – no one can. ... Among the worst attrition rates in the industry. 99.6% of all trials in Alzheimer’ s disease (AD)

  • Atlantis Healthcare

    Alzheimer’ s disease. • prostate cancer. • leukaemia. • chronic obstructive pulmonary disease. • ... It’ s enlightening to see such an innovative support programme aimed at tackling some of the fundamental issues in [this disease], including

  • PharmiWeb Solutions

    Some of the world's largest pharmaceutical companies choose us for mission critical digital programmes. ... difference. A new and innovative drink for the dietary management of early Alzheimer’ s disease.

More from PMHub
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics